Skip to content

Ease of Use Study of the FemPulse System

Ease of Use Study of the FemPulse System

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06885099
Enrollment
11
Registered
2025-03-20
Start date
2025-02-11
Completion date
2025-07-31
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder (OAB)

Keywords

neuromodulation

Brief summary

The objective of the study is to demonstrate that the FemPulse System can be used as indicated

Detailed description

The objective of the study is to demonstrate that the FemPulse System can be used as indicated in the Patient and Clinician Instructions for Use (IFU), as applicable.

Interventions

Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.

Sponsors

FemPulse Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: 1. Females, defined as a person with a cervix, ≥21 years old, with OAB symptoms, as confirmed by a physician. OAB is defined by urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence with symptoms . 2. Able to read, comprehend, and reliably provide informed consent and study-related information. 3. Willing and able to comply with study required procedures and visits

Exclusion criteria

1. Any significant pain, neurologic, psychological condition or other factors, that in the investigator's judgment, might confound the protocol study assessments, and adherence to the protocol. 2. Has a metal pelvic implant or an active implantable medical device, including but not limited to a cardiac pacemaker, cardioverter-defibrillator or neurostimulator 3 History of a cardiac condition including, but not limited to, clinically significant abnormal ECG or arrhythmia that may interfere with study participation as determined by investigator. 4\. Systemic condition or disease that may interfere with study participation or not an appropriate study candidate, as determined by study investigator.

Design outcomes

Primary

MeasureTime frameDescription
Patient Usability of System2 daysA survery will be conducted to determine the overall usability of the system

Countries

United States

Contacts

STUDY_DIRECTORRoshini Jain

FemPulse Corporation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026